Tango Therapeutics Inc (NAS:TNGX)
$ 9.982 0.31 (3.2%) Market Cap: 1.07 Bil Enterprise Value: 752.88 Mil PE Ratio: 0 PB Ratio: 4.18 GF Score: 52/100

Tango Therapeutics Inc at H.C. Wainwright Precision Oncology Conference (Virtual) Transcript

Nov 14, 2022 / 04:00PM GMT
Release Date Price: $8.15 (+5.03%)
Robert Burns
H.C. Wainwright & Co. - Analyst

Welcome to the next fireside chat with Tango Therapeutics. I'm Robert Burns, Managing Director and Senior Biotech Analyst at H.C. Wainwright. And I'm joined today by Barbara Weber, the CEO of Tango. Barbara, thank you for joining us today.

Barbara Weber
Tango Therapeutics, Inc. - President and CEO

Thanks for having me.

Questions & Answers

Robert Burns
H.C. Wainwright & Co. - Analyst

So why don't we just dive right in? For those who may be unfamiliar with Tango, could you provide a brief overview of the company's screening platform as well as its pipeline?

Barbara Weber
Tango Therapeutics, Inc. - President and CEO

Yes, thanks. Starting with really the basic idea is that there are activated oncogenes in cancer that can be targeted. But equally important, there are tumor suppressor genes that are lost. And tumor suppressor genes that are lost cannot be directly targeted because they're gone or functionally

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot